A purchasing lead's practical checklist for evaluating surgical and diagnostic equipment in 2025 — including what the Globus Medical/Nevro deal changes, why a slit lamp review should look different from a PCR machine review, and the total-cost math that has saved us roughly $140K since 2023.

When to use this checklist

If you're a purchasing lead, OR manager, or biomedical engineering director staring down a 2025 capital equipment budget — spine implants, surgical navigation, patient monitoring, dental gear, diagnostic units like a slit lamp or a PCR machine, or anything in the neuromodulation space (deep brain stimulators, spinal cord stimulators) — this checklist is for you.

I handle capital equipment purchasing for a 470-bed hospital network. I've been doing this for 8 years. In that time I've personally made 9 significant procurement mistakes totaling roughly $470K in wasted budget — about $180K of that on surgical hardware and diagnostic equipment that was either miscategorized, mishandled at the service-contract level, or blind-sided by a supplier merger we didn't see coming. So I maintain the checklist our team now uses. It has 7 steps. Here they are.

One note before we start: 2025 is a strange year to be evaluating neuro and spine vendors. The Globus Medical acquisition of Nevro closed, and that changes the service-contract math for any hospital that already runs Globus navigation (ExcelsiusGPS) or Nevro spinal cord stimulators. If you're comparing them against Medtronic or Stryker right now, the checklist below is the one I'd use.

Step 1: Nail down the FDA product code before you email a single vendor

This is the step most people skip, and it's the one that gets you in trouble 6 months later when the device shows up and your receiving team flags it for a different regulatory class than what procurement approved.

Ask yourself: what is the specific FDA product code for this device? Not the category. The code. A deep brain stimulator (DBS) is a Class III device with a very different regulatory footprint than a slit lamp (Class II, ophthalmology). A PCR machine may sit in Class I or II depending on its intended use and whether it's used for IVD assays. If your team has been treating all of these as "medical equipment" in the same approval template, you're one audit away from a bad quarter.

The way I do it now: I pull the device's 510(k) or PMA number directly from the FDA's public 510(k) database and paste it into our requisition form. It takes 4 minutes. In 2021, I skipped that step on a Class III neuromodulation order and we ended up having to re-run the entire approval through a different committee — 3-week delay, roughly $4,200 in admin and rescheduling costs.

Per FDA guidance, Class III devices (including deep brain stimulators) require Premarket Approval (PMA) before marketing, while most Class II devices — spine implants, slit lamps, ultrasound systems — clear through the 510(k) pathway. Source: fda.gov/medical-devices.

Step 2: Get written confirmation of post-merger product continuity

This is the step where the Globus Medical/Nevro situation changes the calculus in 2025.

When two vendors merge, the first thing that usually changes is not the product — it's the service and support layer. Contracts get re-papered. Field service territories shift. Sometimes a product line that was fully supported in Q4 becomes "legacy" by Q2. I learned this the hard way in September 2022, when a mid-size supplier we'd used for years was acquired and our signed service agreement got reclassified as a legacy contract. Our response time went from 48 hours to 9 days. We had a patient-monitoring unit down for a week and a half.

So now, before we sign anything from a vendor that has been through an acquisition in the last 24 months, we ask for a one-page letter confirming:

• Product line continuity for at least 36 months post-close
• Service coverage in our state and the adjacent 2 states
• Whether spare parts pricing changes at renewal

If they can't produce that letter, I treat the bid as higher-risk even if the unit price is lower. Honestly, that's the trade-off nobody puts on the slide deck: the lowest bid is often the one with the murkiest continuity language.

Step 3: Separate "evaluation" from "procurement" — they're not the same meeting

I used to run one combined meeting where clinical, procurement, and IT would evaluate the device and the contract in the same 90 minutes. Big mistake. The clinicians talk about workflow and the procurement team talks about line-item pricing and nobody actually checks whether the clinical need maps to the pricing tier we're being quoted.

Now we do this:

1. Evaluation meeting (60 min): clinical stakeholders only. Output: a one-page needs list with specific use cases, volume estimates, and must-have specs.
2. Procurement meeting (45 min): procurement + finance. Output: total cost of ownership model that maps specs back to the needs list, line by line.
3. Joint sign-off (30 min): both groups confirm the tier and service package align.

On a recent slit lamp replacement order — nothing exotic, just a routine ophthalmology refresh — this separation caught a $9,800 mismatch between the tier the vendor proposed and the actual usage profile our ophthalmology lead described. We would have overshot. That's a lot of money for a device with a single primary use case.

Step 4: Map compatibility, not just specs

Healthcare equipment doesn't live in a vacuum. Before you sign, list every adjacent system the device needs to talk to.

The obvious ones: surgical navigation ↔ imaging ↔ spine implants. But it goes deeper. Does the new deep brain stimulator programming interface integrate with your existing EEG/neuromodulation workflow, or does it require a firmware upgrade on systems you already own? Does the PCR machine's software talk to your LIS, or will the lab run it as a stand-alone? A slit lamp is mostly self-contained — but if you're buying the imaging-attachment version, that attachment needs to export to your ophthalmology PACS.

I'm not an IT integration specialist, so I can't tell you which middleware layer is going to conflict. What I can tell you from a procurement perspective is: put the compatibility questions on paper and make the vendor respond to each one. When we started doing that, we caught missing integrations on 3 of our last 11 equipment orders. Total repair cost avoided: roughly $34,000.

Step 5: Calculate total cost of ownership from day-one patient use

Here's the thing about the sticker price: it's the smallest number on the page.

Total cost of ownership for medical equipment usually includes:

• Capital unit price
• Installation and commissioning fees
• Consumables (probes, electrodes, reagents, single-use kits)
• Preventive maintenance contract
• Software licensing or subscription
• Training (often bundled once, then billable)
• Disposal or trade-in at end of life

On a surgical navigation order in 2023, the unit price was 58% of the 5-year TCO. The service and software line items together were 31%. If we'd only compared unit prices against the competing bid, we would have picked the vendor whose total cost was roughly $62,000 higher over the 5-year horizon.

This gets into accounting territory, which isn't my expertise. What I'd recommend: loop in whoever runs your capital budget model and make them sign the TCO number before the PO goes out. That signature alone has saved our team more arguments than any policy document.

Step 6: Confirm regional service coverage in writing

I don't care how good the device is — if the nearest field engineer is 3 states away, your uptime math changes.

Globus Medical is headquartered in Audubon, Pennsylvania (globus medical pa), and that geography matters if you're buying on the East Coast. If you're in the Mountain West, ask the exact question: who is my Tier 1 service contact, what's their physical location, and what's the contractual response window? Put all three on the PO.

Look, I'm not saying smaller or regionally-thin vendors are automatically bad. I'm saying the risk is asymmetric, and you should price that risk into the bid comparison. We now apply a 3–7% risk premium to any vendor without a confirmed service center within our state. That's not scientific, but it forces the conversation.

Step 7: Route the PO through a pre-signature review — every time

This is the boring one. It's also the one that catches the most errors.

The pre-signature review is 20 minutes and covers 6 items:

1. Does the device name on the PO match the device name on the 510(k) clearance?
2. Is the product code correct?
3. Is the service-tier language consistent with what procurement negotiated?
4. Are consumables listed with unit prices and renewal terms?
5. Is the payment schedule matched to delivery and acceptance milestones?
6. Is the vendor's banking/remittance information verified against our master vendor file?

Since we started running this in Q1 2024, we've caught 47 potential errors across roughly 210 equipment orders. About 6 of those would have been significant — wrong product code, wrong tier, one near-miss on remittance fraud. The 20 minutes is the easiest ROI on this entire list.

Per FTC guidance, businesses should verify vendor identity and bank details before issuing payment to a new or changed supplier — invoice and payment-redirection fraud is a documented B2B risk. Source: ftc.gov/business-guidance.

What usually goes wrong (and where I've burned budget)

A few common mistakes, from someone who has made them:

Don't skip the merger check. If the vendor you're evaluating has been through an acquisition in the last 2 years — which is exactly the situation with the Globus Medical/Nevro deal in 2025 — ask for the continuity letter in step 2. It's the single most common source of surprise cost in our equipment category.

Don't evaluate devices from the same template. A slit lamp, a PCR machine, and a deep brain stimulator should not go through the same procurement meeting structure with the same weight on each question. The slit lamp is a commodity refresh. The DBS is a clinical-program decision with a decade-long tail. Match your process intensity to the device category, not to the size of the quote.

Don't trust verbal promises on service turnaround. Get it in the contract. Get the penalty language in the contract. I once accepted a verbal "48-hour guarantee" on a patient monitoring support renewal. It was not in the contract. It was not 48 hours. That one cost us roughly $11,000 in rented replacement units over a single month.

I can only speak to what has worked for a 470-bed domestic hospital network with reasonably predictable capital cycles. If you're running a multi-site IDN or an international deployment, the risk weighting will shift. But the 7 steps themselves — regulatory code, merger continuity, evaluation separation, compatibility, TCO, service coverage, pre-signature review — are the ones I'd keep no matter the scale. They've saved us about $140K since 2023. That's not a marketing number. That's what's on our internal error-tracking sheet.